Abstract
Introduction Renal cell carcinomas (RCC) are collectively the third most common type of genitourinary neoplasms, surpassed only by prostate and bladder cancer. Cure rates for renal cell carcinoma are related to tumor grade and stage; therefore, diagnostic methods for early detection and new therapeutic modalities are of paramount importance. Epigenetics can be defined as inherited modifications in gene expression that are not encoded in the DNA sequence itself. Epigenetics may play an important role in the pursuit of early diagnosis, accurate prognostication and identification of new therapeutic targets. Material and methods We used PubMed to conduct a comprehensive search of the English medical literature using search terms including epigenetics, DNA methylation, histone modification, microRNA regulation (miRNA) and RCC. In this review, we discuss the potential application of epigenetics in the diagnosis, prognosis and treatment of kidney cancer. Results During the last decade, many different types of epigenetic alterations of DNA have been found to be associated with malignant renal tumors. This has led to the research of the diagnostic and prognostic implications of these changes in renal malignancies as well as to the development of novel drugs to target these changes, with the aim of achieving a survival benefit. Conclusions Epigenetics has become a promising field in cancer research. The potential to achieve early detection and accurate prognostication in kidney cancer might be feasible through the application of epigenetics. The possibility to reverse these epigenetic changes with new therapeutic agents motivates researchers to continue pursuing better treatment options for kidney cancer and other malignancies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 157-164 |
| Number of pages | 8 |
| Journal | Central European Journal of Urology |
| Volume | 68 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2015 |
Fingerprint
Keywords
- DNA methylation
- Histone modification
- Kidney cancer
- MicroRNA regulation
ASJC Scopus subject areas
- Urology
Cite this
The role of Epigenetics in Kidney malignancies. / Harb-De la Rosa, Alfredo; Acker, Matthew; Swain, Sanjaya; Manoharan, Murugesan.
In: Central European Journal of Urology, Vol. 68, No. 2, 2015, p. 157-164.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The role of Epigenetics in Kidney malignancies
AU - Harb-De la Rosa, Alfredo
AU - Acker, Matthew
AU - Swain, Sanjaya
AU - Manoharan, Murugesan
PY - 2015
Y1 - 2015
N2 - Introduction Renal cell carcinomas (RCC) are collectively the third most common type of genitourinary neoplasms, surpassed only by prostate and bladder cancer. Cure rates for renal cell carcinoma are related to tumor grade and stage; therefore, diagnostic methods for early detection and new therapeutic modalities are of paramount importance. Epigenetics can be defined as inherited modifications in gene expression that are not encoded in the DNA sequence itself. Epigenetics may play an important role in the pursuit of early diagnosis, accurate prognostication and identification of new therapeutic targets. Material and methods We used PubMed to conduct a comprehensive search of the English medical literature using search terms including epigenetics, DNA methylation, histone modification, microRNA regulation (miRNA) and RCC. In this review, we discuss the potential application of epigenetics in the diagnosis, prognosis and treatment of kidney cancer. Results During the last decade, many different types of epigenetic alterations of DNA have been found to be associated with malignant renal tumors. This has led to the research of the diagnostic and prognostic implications of these changes in renal malignancies as well as to the development of novel drugs to target these changes, with the aim of achieving a survival benefit. Conclusions Epigenetics has become a promising field in cancer research. The potential to achieve early detection and accurate prognostication in kidney cancer might be feasible through the application of epigenetics. The possibility to reverse these epigenetic changes with new therapeutic agents motivates researchers to continue pursuing better treatment options for kidney cancer and other malignancies.
AB - Introduction Renal cell carcinomas (RCC) are collectively the third most common type of genitourinary neoplasms, surpassed only by prostate and bladder cancer. Cure rates for renal cell carcinoma are related to tumor grade and stage; therefore, diagnostic methods for early detection and new therapeutic modalities are of paramount importance. Epigenetics can be defined as inherited modifications in gene expression that are not encoded in the DNA sequence itself. Epigenetics may play an important role in the pursuit of early diagnosis, accurate prognostication and identification of new therapeutic targets. Material and methods We used PubMed to conduct a comprehensive search of the English medical literature using search terms including epigenetics, DNA methylation, histone modification, microRNA regulation (miRNA) and RCC. In this review, we discuss the potential application of epigenetics in the diagnosis, prognosis and treatment of kidney cancer. Results During the last decade, many different types of epigenetic alterations of DNA have been found to be associated with malignant renal tumors. This has led to the research of the diagnostic and prognostic implications of these changes in renal malignancies as well as to the development of novel drugs to target these changes, with the aim of achieving a survival benefit. Conclusions Epigenetics has become a promising field in cancer research. The potential to achieve early detection and accurate prognostication in kidney cancer might be feasible through the application of epigenetics. The possibility to reverse these epigenetic changes with new therapeutic agents motivates researchers to continue pursuing better treatment options for kidney cancer and other malignancies.
KW - DNA methylation
KW - Histone modification
KW - Kidney cancer
KW - MicroRNA regulation
UR - http://www.scopus.com/inward/record.url?scp=84931828331&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931828331&partnerID=8YFLogxK
U2 - 10.5173/ceju.2015.453
DO - 10.5173/ceju.2015.453
M3 - Article
AN - SCOPUS:84931828331
VL - 68
SP - 157
EP - 164
JO - Central European Journal of Urology
JF - Central European Journal of Urology
SN - 2080-4806
IS - 2
ER -